Patents Examined by M Franco G Salvoza
  • Patent number: 10689420
    Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: June 23, 2020
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Terence Flotte, Jun Xie
  • Patent number: 10682407
    Abstract: A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV). Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 16, 2020
    Assignee: Monash University
    Inventors: Fasseli Joseph Coulibaly, Ashley Scott Mansell, Rosemary Ann Ffrench
  • Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Patent number: 10655108
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: May 19, 2020
    Assignee: Seqirus UK Limited
    Inventors: Jens-Peter Gregersen, Holger Kost
  • Patent number: 10653627
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: May 19, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventor: Noel Yves Henri Jean Genin
  • Patent number: 10641768
    Abstract: The present disclosure describes methods and kits for reducing interferences in immunoassays performed on solid phase and on samples containing serum or plasma, by adding an effective amount of a polycationic derivative of dextran to the assay.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: May 5, 2020
    Assignee: ABBOTT JAPAN CO. LTD.
    Inventors: Toru Yoshimura, Kenju Fujita
  • Patent number: 10634589
    Abstract: Methods of inactivation of a virus in a sample comprising a protein component are provided. Also provided are methods of reducing protein degradation or modification in to the presence of a reactive species, such as a reactive species generated as a result of UV exposure, are also provided. In another aspect, a method of reducing oxidation of methionine residues, tryptophan residues or both methionine and tryptophan residues in a protein subjected to UV light is provided. The disclosed methods can be performed at any scale and can be automated as desired.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: April 28, 2020
    Assignee: AMGEN INC.
    Inventors: Joseph Edward Shultz, Roger Hart, Brent Welborn
  • Patent number: 10633431
    Abstract: The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies—RYB1, RYB2 and RYB3—and of a composition based thereon for the prevention and treatment of hepatitis C. Said antibodies are produced by cultivation using hybrid BIONA-RYB1, BIONA-RYB2 and BIONA-RYB3. The effectiveness of the antibodies is due to said antibodies binding epitopes, namely Ep1, Ep2 and Ep3 of E2 protein of the hepatitis C viral envelope, respectively. The present invention has demonstrated a neutralizing activity of the antibodies in a model system of infection of human cells in a culture. It has been shown that use of the claimed group of inventions provides for more reliable antibody binding of the hepatitis C virus.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: April 28, 2020
    Inventors: Tatiana Nikolaevna Vlasik, Armen Sergeevich Sadgyan, Igor Nikolaevich Rybalkin, Alexandr Yasenovich Shevelev
  • Patent number: 10626376
    Abstract: Methods for isolating and optionally purifying AAV particles grown in cell cultures using a combination of lyotropic salts, removal of insoluble producer cell debris and DNA, and optional fractionation by hydrophobic interaction chromatography are described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 21, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: David Joseph McNally, Bryan Andrew Piras, Michael Martin Meagher
  • Patent number: 10624935
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 21, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
  • Patent number: 10596252
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: November 4, 2018
    Date of Patent: March 24, 2020
    Assignee: CureVac AG
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Patent number: 10596210
    Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 24, 2020
    Assignees: Virttu Biologics, The university of Sheffield
    Inventors: Joe Conner, Munitta Muthana, Claire Elizabeth Lewis
  • Patent number: 10568917
    Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Dong Min Kang, Sang Hyeon Kang
  • Patent number: 10568957
    Abstract: Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: February 25, 2020
    Assignee: Bharat Biotech International Ltd.
    Inventors: Krishna Mohan Vadrevu, Sai Devarajulu Prasad
  • Patent number: 10555997
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 11, 2020
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 10556003
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: February 11, 2020
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Antonia Fettelschoss, Martin Bachmann
  • Patent number: 10556005
    Abstract: A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 11, 2020
    Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Chikateru Nozaki, Kazuyoshi Kaminaka, Junichi Matsuda
  • Patent number: 10548964
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 4, 2020
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 10548972
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: February 4, 2020
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10544432
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 28, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira